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INTRODUCTION
In the current decade, transcatheter aortic valve implantation (TAVI) has complemented surgical aortic valve replacement (sAVR) in patients with severe aortic stenosis and at high risk for surgery, because it demonstrated comparable mid-term results and improved the quality of life soon after the procedure [1] [2] [3] [4] .
For otherwise operable patients, sAVR remains the treatment of choice that has been shown to improve patients' survival [5] .
Guidelines recommend the use of aortic valve (AV) bioprostheses in patients >60 years or with contraindications for lifelong anticoagulation [6] . However, with the recent advancements and encouraging outcomes of valve-in-valve (ViV) procedures, surgeons often implant bioprostheses instead of mechanical valves more liberally during the index procedure [7] . Thus, an increase †The first author and the last author contributed equally to this work.
in the number of patients presenting with failing bioprosthetic surgical valves in need of a reoperation is to be expected. Conventional redo sAVR (re-sAVR) is regarded as the gold standard for patients with degenerated aortic bioprostheses and is associated with an acceptable in-hospital mortality rate of up to 5.1% [8, 9] , despite the common inclusion of patients with prosthetic valve endocarditis. Valve-in-valve transcatheter aortic valve implantation (ViV TAVI) could therefore become a novel, less invasive treatment for failing bioprostheses in patients at higher surgical risk, often precluding the standard procedure. Indeed, a number of studies have shown the feasibility and safety of the ViV approach [10, 11] in this clinical scenario, but a comprehensive evaluation of the performance of ViV TAVI compared with re-sAVR has not yet been performed.
Our objective was to compare the clinical and echocardiographic outcomes of patients presenting with symptomatic degenerated AV bioprostheses undergoing ViV TAVI with those who were treated with conventional surgical redo AV replacement.
METHODS

Data sources and search strategy
This systematic review and meta-analysis was performed in accordance with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) statement [12] . The MOOSE checklist is available as Supplementary Material, Table S1 . We searched the PubMed, EMBASE, CINAHL, Web of Science, Cochrane Register of Controlled Clinical Trials (CENTRAL) databases and Google Scholar as well as proceedings from major cardiothoracic and cardiology society meetings through the end of February 2017 for relevant studies. Abstracts were eligible for detailed assessment if they were available online and reported outcomes of interest. Search terms were 'transcatheter aortic valve-in-valve implantation or replacement-', 'redo surgical aortic valve implantation or replacement-', 'transcatheter aortic valve-in-valve versus redo surgical aortic valve implantation or replacement-', 'TAVR-', 'redo TAVR-', 'TAVI-', 'redo TAVI-', 'ViV TAVI", 'AVR-', 'redo AVR-', 're-sAVR', 'randomized-', 'retrospective case control-' and 'study/ trial'. The literature was limited to articles published in English. References of original articles were reviewed manually and crosschecked for other relevant reports. Authors of original articles were contacted for missing data of interest.
Selection criteria, quality assessment and outcomes
Studies were included if they met all of the following criteria: (i) they described a human study; (ii) they compared ViV TAVI with conventional sAVR for degenerated aortic bioprostheses and (iii) they reported outcomes of interest. Studies were excluded if (i) they were a single-arm design; (ii) the patients reported on had no previous cardiac operation or (iii) the patients had previous cardiac surgery but no differentiation with regard to the index procedure. No restrictions concerning the types of both failed and implanted aortic bioprotheses, stents and structures were made. Narrative reviews and case reports were not considered.
Two independent reviewers (M.G. and M.K.) selected the studies for inclusion and extracted data related to the patient characteristics of interest and the relevant outcomes. Two authors (M.G. and M.K.) independently assessed the eligibility of the trials and the risk of bias. Risk of bias at the level of the individual study was assessed using the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool [13] .
Selection of end-points
The end-points were selected in accordance with the Valve Academic Research Consortium-2 [14] definitions (Supplementary Material, Table S2 ). The primary clinical outcome was all-cause mortality at the end of the longest available follow-up period. The remaining 30-day outcomes assessed were cardiovascular deaths, myocardial infarction (MI), stroke, bleeding complications, acute kidney injury, vascular complications and permanent pacemaker implantation. In addition, the following non-Valve Academic Research Consortium-2 outcomes were also considered: readmission and length of stay in the intensive care unit (ICU) and in the hospital. The primary echocardiographic outcome was the mean postoperative AV gradient. Secondary echocardiographic outcomes of interest were paravalvular leak and patient-prosthesis mismatch (PPM).
Statistical analysis
Data were analysed according to the intention-to-treat principle wherever applicable. Risk ratios (RRs) and 95% confidence intervals (CIs) served as the primary index statistics for dichotomous outcomes; for continuous outcomes, the weighted mean difference (MD) and the corresponding 95% CIs were calculated using the random effects model as a more conservative approach for observational data, which accounted for between-and withinstudy variabilities. To corroborate the results and account for the potential differences in follow-up duration, the analysis of allcause mortality and readmission rates (as assessed at the longest available follow-up) was performed with hazard ratios (HRs). Where available, we digitized the Kaplan-Meier curves using Engauge Digitizer 9.5 (Mark Mitchell, Torrance, CA, USA) and reconstructed time-to-event data using the algorithm specified by Guyot et al. [15] for the longest available survival data. Whenever available, we used published estimates. If no published estimates were available, we derived estimates from reconstructed time-to-event data of individual studies using Cox regression. The exact marginal likelihood method was used to handle potential tied event failures. Analyses to obtain HRs of single studies were performed in Stata 13.0 (StataCorp, College Station, TX, USA). The statistical inconsistency test,
, where Q is the v 2 statistic and df is degree of freedom, was used to assess heterogeneity. An I 2 value of less than 40% indicated no obvious heterogeneity; values between 40% and 70% were suggestive of moderate heterogeneity; and I 2 > 70% was considered high heterogeneity. Review Manager V.5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark) was used for the remaining statistical computations. The P-values of < _0.05 were considered statistically significant and reported as 2 sided, without adjustment for multiple comparisons.
RESULTS
The study selection process and reasons for excluding some studies are described in Supplementary Material, Fig. S1 . A systematic search of the online databases returned 416 potentially eligible records that were retrieved for scrutiny. Of those, 411 were excluded, because they were not pertinent to the design of the meta-analysis or did not meet the explicit inclusion criteria. Five retrospective series [16] [17] [18] [19] [20] (including 1 matched cohort study [16] ) enrolling 342 patients were eventually included in the analysis. The patients were divided into 2 groups: the ViV TAVI (n = 176) group and the re-sAVR (n = 166) group. Decisions regarding the allocation of the patients to the groups were made by a designated heart team in each study; Supplementary Material, Table S3 lists exclusion and eligibility criteria within single studies. Patients in the ViV TAVI group were on average 5 years older than those in the re-sAVR group (MD 5.25, 95% CI 1.50-8.99; P = 0.006) and were at higher baseline risk as assessed by EuroSCORE (MD 7.67, 95% CI 2.93-12.41; P = 0.002). The elapsed time from the index procedure to valve deterioration ranged from 8.0 ± 3.9 to 10.0 ± 4.8 years and from 7.2 ± 4.8 to 10.0 ± 4 years in ViV TAVI-and re-sAVR-treated patients, respectively. A summary of the studies and of the baseline characteristics of the patients is shown in Table 1 .
The transfemoral route was the most commonly used route during the ViV TAVI procedure (54%), followed by the transapical (39%) and transaortic access (6%); subclavian and carotid access comprised <1% of cases. Balloon-expandable Edwards Sapien and Sapien XT (Edwards Lifesciences Inc., Irvine, CA, USA) valves were used most frequently (60%). Stented valve prostheses and, in particular, the Edwards Perimount (Edwards Lifesciences Inc.) were the most commonly implanted valves in patients in the re-sAVR arm. One study reported on patients undergoing surgical valve replacement with sutureless Perceval (LivaNova, Sorin group, Saluggia, Italy) bioprostheses [19] . Detailed procedural characteristics along with operative times are reported in Supplementary Material , Table S4 . The need to perform a concomitant revascularization procedure was an exclusion criterion in all but 1 study [18] ; only 1 patient underwent percutaneous coronary intervention in the ViV TAVI arm group, whereas 5 patients underwent coronary artery bypass grafting in the resAVR group. Risk of bias for each study across each of the 7 riskof-bias domains is presented in Supplementary Material, Table  S5 . Overall, the studies reported either moderate or serious risk of bias. Given the overall high risk of bias along with the limited number of studies, all articles were retained for the purposes of this review. Most commonly, biases arose from the selection of participants for the study and the subjective distribution of the participants within the study arms by designated heart teams.
Primary outcome
All 5 studies (342 patients) were included in the analysis of allcause mortality. Stratified by procedural and 30-day time frames, all-cause mortality was not statistically different between the ViV TAVI and the re-sAVR procedures (RR 0.74, 95% CI 0.18-2.97; P = 0.67; I 2 = 0%; Fig. 1A ) and RR 1.29, 95% CI 0.44-3.78; P = 0.64; I 2 = 0%; Fig. 1B ), respectively. Procedural survival was 97.6% vs 96.5%, whereas 30-day survival was 94.6% vs 96.4% for ViV TAVI and re-sAVR, respectively. The follow-up period in an analysis of cumulative survival with estimates derived from reconstructed time-to-event data of individual trials was 18.1±7.5 months. Within these time frames, ViV-TAVI was associated with borderline significantly worse long-term survival rates compared to resAVR (HR 1.91, 95% CI 1.03-3.57; P = 0.039; I 2 = 13%; Fig. 1C ).
Primary echocardiographic outcomes
Two studies [16, 20] (174 patients) reported preoperative mean AV gradients that were lower by nearly 5 mmHg in the ViV TAVI than in the re-sAVR group (MD -4.70, 95% CI -9.67 to -0.27; P = 0.068). Postoperative AV gradients ranged from 11.8 ± 3.2 to 19.7 ± 7.7 mmHg in the ViV TAVI and from 12.2 ± 5.7 to 15.9 ± 3.5 mmHg in the re-sAVR groups, with no statistically significant differences in the summary analysis (4 studies; 328 patients) (MD 1.98, 95% CI -4.55 to -8.52; P = 0.55; I 2 = 95%; Fig.  2A) . Similarly, no statistically significant differences were noted in the analysis of >20 mmHg AV gradient (n = 4; N = 328; RR 3.66, 95% CI 0.44-30.58; P = 0.23; I 2 = 75%; Fig. 2B ).
Secondary clinical outcomes
Three studies and 196 patients contributed data for the analysis of 30-day cardiovascular mortality; with an incidence of 5.8%
(6 of 104) and 6.5% (6 of 92), there was no difference between the ViV TAVI and re-sAVR groups, respectively (RR 0.91, 95% CI 0.30-2.70; P = 0.86; I 2 = 0%; Fig. 3A) . Similarly, there were no statistical differences between the ViV TAVI and re-sAVR groups with regard to 30-day risk of MI (4 studies; 298 patients; RR 1.62, 95% CI 0.38-6.94; P = 0.51; I 2 = 0%; Fig. 3B ), stroke (5 studies = 5; 342 patients; RR 0.62, 95% CI 0.16-2.42; P = 0.49; I 2 = 0%; Fig. 3C ) and acute kidney injury (5 studies; 342 patients; RR 0.71, 95% CI 0.22-2.30; P = 0.57; I 2 = 52%; Fig. 3D ). ViV TAVI was associated with a 63% statistically significant lower risk of permanent pacemaker implantation; 12 of 176 (6.8%) and 31 of 166 (18.7%) patients who had ViV TAVI and resAVR, respectively, required pacemakers (RR 0.37, 95% CI 0.20-0.68; P = 0.002; I 2 = 0%; Fig. 4A ). Bleeding events were statistically less common in the ViV TAVI compared with the re-sAVR group (RR 0.33, 95% CI 0.17-0.65; P = 0.001; I 2 = 0%; Fig. 4B ). Corresponding bleeding rates were 9.6% (10 of 104) and 28.3% (26 of 92) for ViV TAVI and re-sAVR groups, respectively. Fewer vascular complications were seen in the re-AVR group: the ViV TAVI procedure was associated with a greater than 5.5-fold borderline significantly increased risk of minor vascular complications (RR 5.63, 95% CI 1.00-31.81; P = 0.050; I 2 = 0%) and a 2-fold increased risk of major vascular complications without reaching statistical significance (RR 2.09, 95% CI 0.67-6.56; P = 0.21; I 2 = 0%). The overall risk of vascular complications was significantly elevated in patients treated with ViV TAVI compared to those treated with re-sAVR (RR 3.72, 95% CI 1.38-10.05; P = 0.010; I 2 = 0%; Fig. 4C ). The length of stay in the ICU (5 studies; 342 patients) was significantly reduced in the ViV TAVI group compared with the re-sAVR group and was on average nearly 2.5 days shorter (MD -2.42, 95% CI -3.21 to -1.64; P < 0.001; I 2 = 66%; Supplementary Material Fig.  2A) . Similarly, the length of the hospital stay (4 studies; 212 patients) was significantly shorter (by nearly 3.5 days) in the ViV TAVI compared with the re-sAVR group (MD -3.35, 95% CI -6.13 to -0.57; P = 0.020; I 2 = 96%; Supplementary Material, Fig. S2B ). An analysis of readmissions demonstrated a non-significant increase in readmissions in the ViV TAVI compared with the resAVR group (HR 1.97, 95% CI 0.88-4.40; P = 0.098; I 2 = 0%; Fig. 4D ).
Secondary echocardiographic outcomes
Analysis of studies with a focus on the echocardiographic incidence of PPM (3 studies; 196 patients) demonstrated a significantly increased risk of PPM in the ViV TAVI compared with the re-sAVR group; PPM were observed in 16.4% (17 of 104) vs 4.4% (4 of 92) of patients, respectively (RR 4.10, 95% CI 1.45-11.58; P = 0.008; I 2 = 0%; Supplementary Material, Fig. S3A ). Analysis of the incidence of paravalvular leak (5 studies; 342 patients) favoured re-sAVR; a corresponding event rate of 5.5% (8 of 145) for re-sAVR compared with 21.1% (36 of 171) was seen in the ViV TAVI group; the transcatheter approach was associated with a greater than 4.5-fold significant increase in the risk of paravalvular leak (RR 4.65, 95% CI 1.24-17.46; P = 0.023; I 2 = 38%; Supplementary Material, Fig. S3B ).
Additional analyses
We also evaluated all other TAVI-only-related complications reported in the included articles. Conversion to open surgery, unplanned use of cardiopulmonary bypass, coronary obstruction, ventricular septal perforation, mitral valve apparatus damage or dysfunction, cardiac tamponade, valve endocarditis, valve thrombosis or valve malpositioning and the use of more than 1 valve prosthesis accounted for a total of 9.1% (16 of 176) of patients in the ViV TAVI group.
As a sensitivity analysis for the primary echocardiographic outcome, we excluded the study by Grubitzsch et al. [18] , because, unlike the other reports, the authors included only patients with degenerated stentless bioprostheses; thus, in the ViV TAVI group, larger diameter valves could have been implanted in the annuli, thereby moving the direction of the estimates for the mean postoperative AV gradient and >20 mmHg gradient towards null. Indeed, after we excluded the study by Grubitzsch et al., the mean postoperative AV gradient was significantly reduced in the re-sAVR group compared with the ViV TAVI group by nearly 5 mmHg (MD 4.82, 95% CI 1.03-8.61; P = 0.017; I 2 = 70%; Supplementary Material, Fig. S4A) . Similarly, the ViV TAVI group was associated with a nearly 10-fold statistically significant increase in the risk of a postoperative >20 mmHg AV gradient: (3 studies; 276 patients) (RR 9.74, 95% CI 3.62-26.19; P < 0.001; I 2 = 0%; Supplementary Material, Fig. S4B ) after exclusion of Grubitzsch et al.
DISCUSSION
The current systematic review and meta-analysis is the first to compare outcomes of ViV TAVI and conventional re-sAVR in patients with failing biological AV prostheses. The principal findings of this article are (i) patients undergoing ViV TAVI were at a significantly higher baseline operative risk compared to those undergoing re-sAVR, yet (ii) in terms of hard clinical outcomes, the analysis demonstrated similarities between patients in the ViV TAVI and re-sAVR groups; (iii) VIV TAVI was associated with shorter stays in the ICU and the hospital together with fewer bleeding complications, yet (iv) re-sAVR was clearly superior to ViV TAVI with regard to postoperative echocardiographic parameters and, in particular, the AV gradient and paravalvular leaks. Because of a recently observed considerable shift towards the implantation of the bioprosthesis, it is expected that patients will increasingly present with degenerated bioprostheses. Treatment of patients with failed bioprostheses is a clinical challenge, given their risk profiles and underlying conditions. Although a conventional redo reoperation is considered, the standard of care, repeat cardiac operations carry significant morbidity and mortality risks in elderly patients, who often present with serious comorbidities [21, 22] . TAVI has become a widely accepted alternative for patients at high surgical risk with severe symptomatic native AV stenosis [7, 23] . The Placement of Aortic Transcatheter Valves (PARTNER) trial [1] demonstrated that in patients with severe aortic stenosis who were not suitable candidates for surgery, TAVI performed with the Edwards SAPIEN heart valve system (Edwards Lifesciences), compared with standard therapy, significantly reduced the rates of death from any cause, the composite end-point of death from any cause or repeat hospitalization and cardiac symptoms, despite the higher incidence of major strokes and major vascular events. The SAPIEN 3 trial [24] , which compared TAVI to sAVR in intermediate-risk patients with severe aortic stenosis, showed a low mortality rate, fewer strokes and fewer cases of regurgitation at 1 year and a significant superiority for composite outcome over TAVI compared with surgery, extrapolating the indications for TAVI as the preferred treatment alternative for intermediate-risk patients. In accordance with those previous findings, the recently available Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients (SURTAVI) trial [25] clearly demonstrated that TAVI was a non-inferior alternative to surgery in patients at intermediate surgical risk who had severe aortic stenosis, with the incidence of the primary composite end-point of death from any cause or disabling stroke at 24 months estimated at 12.6% and 14.0% in the TAVI and surgery groups, respectively. Although 1 recent meta-analysis that compared the outcomes of TAVI versus sAVR in 1899 patients with severe aortic stenosis who were at low or intermediate surgical risk found no significant difference between the 2 treatment options in terms of survival, stroke and MI [26] , the requirement of permanent pacemaker implantation, the incidence of moderate or severe paravalvular regurgitation and major vascular complications were found to be statistically associated with the TAVI procedure. This finding is partially reflected in the current analysis; however, we focused on failing bioprostheses instead of on native stenotic valves.
One principal finding is the safety and feasibility of the ViV TAVI approach in the off-label setting of failing bioprostheses; that finding is consequently reflected by no difference in hard clinical outcomes compared with the standard-of-care re-sAVR. We found 2.38% procedural and 5.41% 30-day all-cause mortality rates in patients having ViV TAVI; the incidence was somewhat lower than that observed in the Global Valve-in-Valve Registry [11] (30-day mortality 8.41%). Admittedly, only 1 study included in this meta-analysis [19] enrolled patients with high EuroSCOREs (33.8 vs 31.1) comparable to those of patients in the Valve-in-Valve Registry. That being said, the patients in the control arm of this study were at much lower operative risk; in fact, patients undergoing ViV TAVI were on average 5 years older than those undergoing re-sAVR (MD 5.25, 95% CI 1.50-8.99; P = 0.006), and the EuroSCORE in the ViV TAVI subset was almost 8 percentage points higher than that of their surgical counterparts (MD 7.67, 95% CI 2.93-12.41; P = 0.002). The survival analysis possibly reflects the inherent differences between the study groups; during the studies, in the cumulative survival analysis, we observed an accrual of benefit with re-sAVR compared with ViV TAVI (for ViV TAVI vs re-sAVR: HR 1.97, 95% CI 1.13-3.43; P = 0.039) that touched the level of statistical significance. We did not observe significant differences in the rates of cardiovascular deaths, MI, stroke and acute kidney injury; although with novel TAVI devices and growing experience, these differences might accumulate over time in favour of the transcatheter approaches. On the other hand, the stays in the ICU and in the hospital were significantly shorter in the patients treated with ViV TAVI. In one study [16] , the stay in the ICU after ViV TAVI compared with after re-sAVR was 0 h (interquartile range 0-50) vs 68 h (interquartile range 43-98) (P < 0.001). Similarly, the median hospital length of stay was also reduced (5 days vs 10.5 days, P < 0.001) due to the initiation of a fasttrack recovery programme for patients who had the transfemoral ViV procedures whereby they bypassed the ICU and were transferred directly to the surgical unit.
As observed in the global ViV registry, aortic ViV implantation is associated with lower rates of paravalvular leaks, pacemaker implantations, cardiac tamponade and annular rupture and higher rates of valve malpositioning, coronary obstruction and elevated post-procedural gradients compared with native AV TAVI [12] . In addition, we noted increased rates of permanent pacemaker implantation with native AV TAVI in comparison with first-time AVR (21.6% vs 7.5%) [26] . This difference is most likely due to some degree of protection created by the surgical bioprosthesis frame, resulting in diminished compression of the TAVI device on the interventricular basal septum and aortic root, thus protecting the conduction system from injury and the annular ring from rupture. In contrast, re-sAVR in the degenerated bioprosthesis sometimes implies partial excision of the ingrown pannus together with surrounding structures and leads, in turn, to conductivity disorders or loss. We found a 63% statistically significant lower risk of permanent pacemaker implantation with ViV TAVI compared with re-sAVR; indeed, 6.81% and 18.67% of patients who had ViV TAVI and re-sAVR required a permanent pacemaker, which is perfectly in line with the previous observations. One potentially fatal complication, coronary obstruction, was reported in 4 patients in the ViV TAVI and 1 patient in the re-sAVR subset of patients in the current analysis. With numbers so small and precluding any definite analyses, the incidence of coronary obstruction was 1.17%, much lower than previously described (between 2.5% and 3.5%) [12, 27] , given the more frequent use of balloon-expandable TAVI valves, a significant prognostic factor for coronary obstruction during ViV procedures [28] .
Significantly elevated post-procedural gradients are common after VIV procedures. In an analysis from the Global Valvein-Valve Registry [11] , the rate of high post-procedural gradients (defined as a mean AV gradient >20 mmHg) was relatively high (28.4%), and the mean post-procedural gradient (15.9 mmHg) was higher than that observed after procedures performed inside native AVs (10 mmHg). The reduced area available for the functioning valve when implanted inside a surgical bioprosthesis [i.e. reduced effective orifice area (EOA)] and PPM were the possible causes as declared by Dvir et al. [29] . In this analysis, we found postoperative AV gradients ranging from 11.8 mmHg to 19.7 mmHg in the ViV TAVI and from 12.2 mmHg to 15.9 mmHg in the re-sAVR groups with no statistically significant differences in the summary analysis (MD 1.98, 95% CI -4.55 to -8.52 mmHg; P = 0.55). Similarly, no statistically significant differences in the rate of high post-procedural gradients were observed (RR 3.66, 95% CI 0.44-30.58; P = 0.23). Given the arising heterogeneity, we excluded, as a sensitivity analysis, the study by Grubitzsch et al. [18] , for, unlike other researchers, these authors included only patients with degenerated stentless bioprostheses. Not only could large-diameter ViV TAVI valves have been implanted in the aortic annuli, thereby moving the direction of the estimates of the mean postoperative AV gradient and the >20 mmHg gradient towards null, but the baseline dimensions of the annuli of the bioprostheses and the dimensions of the implanted valves differed significantly. The authors admitted that redo surgery resulted more frequently in a reduction in the diameter of the valve compared with the size of the existing stentless valve. Indeed, 83% of the patients had previous stentless AVs sized at 25-29 mm; however, in the ViV TAVI group, nearly 75% of the implanted valves were > _26 mm. In the re-sAVR group, almost 70% were < _25 mm, resulting in a substantial disproportion between the 2 arms. Exclusion of the study by Grubitzsch et al. led to a mean postoperative AV gradient that was significantly reduced in the re-sAVR group compared with the ViV TAVI group by nearly 5 mmHg (MD 4.82, 95% CI 1.03-8.61; P = 0.017) and an anticipated nearly 10-fold statistically significant increase in the risk of a postoperative AV gradient >20 mmHg (RR 9.74, 95% CI 3.62-26.19; P < 0.001), again favouring re-sAVR. Analyses focusing on the echocardiographic incidence of PPM and paravalvular leaks demonstrated an over 4-fold significantly increased risk of those with the ViV TAVI approach.
Limitations
The ViV TAVI approach represents a widely diverse heterogeneous group of procedures; hence, it is difficult to stratify patients according to the type of the numerous surgical valves treated. Stratification according to the mechanism of failure (stenosis versus regurgitation versus both) and according to the size of the bioprosthesis and its influence on clinical outcomes after ViV implantation was not available without individual patient data. The logistic EuroSCORE was used in 3 studies, the EuroSCORE II in 1 study and the Society of Thoracic Surgeons (STS) Predicted Risk of Mortality was used for risk assessment in a third study. Although the ViV TAVI subset was almost 8 percentage points higher than the surgical counterparts, using the EuroSCORE as a stratification score for transcatheter procedures seems limited [30] . Frailty scores were not reported in the original studies.
The findings of the cumulative survival analysis must be interpreted with caution. First, the patients in the ViV TAVI group were older, independently of the EuroSCORE, sicker and otherwise 'non-reoperable' using standard techniques. The worse prognosis for ViV TAVI noted with long-term follow-up might arise from the higher observed postoperative gradients and the worsening heart failure in the ViV TAVI subset, yet might also have accrued from the comorbidities and baseline shorter life expectancy in these patients. Unfortunately, with the limited number of patients available for inclusion in the study, we could not account for that. Similarly, since only 1 of 5 studies reported hemisternotomy for the re-sAVR (15 patients) procedure, we could not determine the benefit of minimally invasive approaches with these patients. At the same time, our report is the first to comprehensively integrate the most recent data in the emerging, albeit still narrow, field of management of failing aortic bioprostheses.
CONCLUSIONS
The ViV approach is a safe, feasible alternative to conventional surgery that may offer an effective, less invasive treatment for patients with failed surgical AV bioprostheses who are inoperable or at high risk. The sAVR should remain the standard of care, particularly in the low-risk population, because it offers superior haemodynamic outcomes with low mortality rates.
